Clinical Trials Browser

liposomal doxorubicin × Lymphoid × 90 days × Clear all

Hodgkin Disease

NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Clinical Trials

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

9-ING-41 in Patients With Advanced Cancers